What is HC Wainwright's Forecast for AKBA FY2024 Earnings?

Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Equities research analysts at HC Wainwright issued their FY2024 earnings per share estimates for shares of Akebia Therapeutics in a research report issued on Tuesday, January 14th. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will earn ($0.34) per share for the year. HC Wainwright currently has a "Buy" rating and a $7.50 target price on the stock. The consensus estimate for Akebia Therapeutics' current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Akebia Therapeutics' Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at $0.42 EPS and FY2028 earnings at $1.42 EPS.

Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The business had revenue of $37.43 million during the quarter, compared to the consensus estimate of $45.66 million. During the same quarter last year, the firm posted ($0.08) earnings per share.

Separately, StockNews.com lowered shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a research report on Wednesday.

Akebia Therapeutics Stock Up 7.3 %

AKBA opened at $2.07 on Friday. Akebia Therapeutics has a 52 week low of $0.80 and a 52 week high of $2.48. The business's 50 day moving average is $1.91 and its two-hundred day moving average is $1.57. The firm has a market cap of $451.63 million, a price-to-earnings ratio of -9.00 and a beta of 0.72.

Institutional Trading of Akebia Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Mercer Global Advisors Inc. ADV raised its stake in shares of Akebia Therapeutics by 40.7% during the second quarter. Mercer Global Advisors Inc. ADV now owns 31,221 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 9,037 shares during the last quarter. Empirical Asset Management LLC acquired a new position in Akebia Therapeutics in the 3rd quarter valued at $44,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Akebia Therapeutics in the 2nd quarter worth $44,000. XTX Topco Ltd acquired a new stake in shares of Akebia Therapeutics in the 3rd quarter worth $58,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Akebia Therapeutics in the third quarter valued at about $59,000. 33.92% of the stock is owned by institutional investors and hedge funds.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.